JP2010534676A5 - - Google Patents

Download PDF

Info

Publication number
JP2010534676A5
JP2010534676A5 JP2010518369A JP2010518369A JP2010534676A5 JP 2010534676 A5 JP2010534676 A5 JP 2010534676A5 JP 2010518369 A JP2010518369 A JP 2010518369A JP 2010518369 A JP2010518369 A JP 2010518369A JP 2010534676 A5 JP2010534676 A5 JP 2010534676A5
Authority
JP
Japan
Prior art keywords
compound
post
patient
traumatic stress
stress disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010518369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534676A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/070948 external-priority patent/WO2009015248A1/en
Publication of JP2010534676A publication Critical patent/JP2010534676A/ja
Publication of JP2010534676A5 publication Critical patent/JP2010534676A5/ja
Pending legal-status Critical Current

Links

JP2010518369A 2007-07-23 2008-07-23 心的外傷後ストレス障害の治療 Pending JP2010534676A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93503607P 2007-07-23 2007-07-23
PCT/US2008/070948 WO2009015248A1 (en) 2007-07-23 2008-07-23 Treatment of post-traumatic stress disorder

Publications (2)

Publication Number Publication Date
JP2010534676A JP2010534676A (ja) 2010-11-11
JP2010534676A5 true JP2010534676A5 (cg-RX-API-DMAC7.html) 2011-08-18

Family

ID=40281815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010518369A Pending JP2010534676A (ja) 2007-07-23 2008-07-23 心的外傷後ストレス障害の治療

Country Status (12)

Country Link
US (1) US20090054403A1 (cg-RX-API-DMAC7.html)
EP (1) EP2182952A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010534676A (cg-RX-API-DMAC7.html)
CN (1) CN101951912A (cg-RX-API-DMAC7.html)
AU (1) AU2008279091A1 (cg-RX-API-DMAC7.html)
CA (1) CA2707858A1 (cg-RX-API-DMAC7.html)
CO (1) CO6260078A2 (cg-RX-API-DMAC7.html)
MX (1) MX2010000937A (cg-RX-API-DMAC7.html)
NZ (1) NZ583193A (cg-RX-API-DMAC7.html)
RU (1) RU2458691C2 (cg-RX-API-DMAC7.html)
SG (1) SG183069A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009015248A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010000938A (es) * 2007-07-23 2010-07-01 Synosia Therapeutics Inc Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
RU2491067C2 (ru) * 2007-08-06 2013-08-27 Байотай Терапис, Инк Способы лечения зависимости
AU2016208412A1 (en) * 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
PT2501234T (pt) * 2009-11-20 2017-12-13 Tonix Pharma Holdings Ltd Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
MY196014A (en) 2013-03-15 2023-03-06 Tonix Pharmaceuticals Inc Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
EP3074525B1 (en) * 2013-11-26 2024-06-26 University of North Texas Health Science Center at Fort Worth Personalized medicine approach for treating cognitive loss
SG10201902203VA (en) 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
RU2614697C1 (ru) * 2016-04-12 2017-03-28 Общество с ограниченной ответственностью "Нормофарм" Нейропротекторное средство
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
US10588890B2 (en) * 2017-05-30 2020-03-17 Biommunity, Inc. Compositions and methods to regulate hormonal cascades in stress disorders
AU2018204843B2 (en) * 2017-07-05 2023-07-27 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating anxiety disorders in patients via renal neuromodulation
WO2019112457A1 (en) 2017-12-04 2019-06-13 BIAL - PORTELA & Cª, S.A. Dopamine-β-hydroxylase inhibitors
BR112020011345A2 (pt) 2017-12-11 2020-11-17 Tonix Pharma Holdings Limited tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
CN109966281B (zh) * 2019-04-11 2021-04-27 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用
JP7618230B2 (ja) * 2019-07-25 2025-01-21 学校法人東京理科大学 精神・神経系の疾患又は症状を治療し、予防し又は改善する剤
CN120882371A (zh) * 2022-11-30 2025-10-31 闪烁实验室有限公司 使用眼睑跟踪的精神药理学系统和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1425017A1 (en) * 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
WO2005079756A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
CN101257907A (zh) * 2005-07-06 2008-09-03 塞普拉科公司 左旋佐匹克隆和抗抑郁剂的组合
US20100105748A1 (en) * 2007-03-16 2010-04-29 David Weinshenker Methods and compositions for treatment of drug addiction
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder

Similar Documents

Publication Publication Date Title
RU2010106014A (ru) Лечение посттравматического стрессового расстройства
RU2007103313A (ru) Комбинация бупропина и другого состава для эффективной потери веса
JP2013544850A5 (cg-RX-API-DMAC7.html)
JP2013537887A5 (cg-RX-API-DMAC7.html)
WO2007137227A1 (en) Treatment for depressive disorders
JP2005539068A5 (cg-RX-API-DMAC7.html)
JP2005523334A5 (cg-RX-API-DMAC7.html)
JP2012036212A5 (cg-RX-API-DMAC7.html)
JP2022519541A (ja) 不安関連障害を処置するための組成物および方法
JP2007513052A (ja) セロトニン再取り込み阻害剤およびアゴメラチンの併用。
KR101816953B1 (ko) 1-[2-(2,4-디메틸-페닐술파닐)페닐]-피페라진의 치료적 용도
JP2009542819A5 (cg-RX-API-DMAC7.html)
JP5553955B2 (ja) 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ
JP2007505156A5 (cg-RX-API-DMAC7.html)
AU2004238381A1 (en) Combination of the analeptic modafinil and an antidepressant for the treatment of depression
US20110039926A1 (en) Use of enantiomer (1s, 2r) milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients
JP5634529B2 (ja) 強迫性障害(ocd)処置用の薬剤の製造のためのアゴメラチンの使用
JP2009542820A5 (cg-RX-API-DMAC7.html)
Lam The importance of early symptom relief in antidepressant treatment: focus on agomelatine
Roller et al. Disease state management: Depression and antidepressants
Roller et al. Depression and antidepressants: Pharmacists have a crucial role in supporting patients living with depression by providing advice and counselling about pharmacological treatments and recommending various strategies to assist these people to improve their quality of life
US20060217394A1 (en) Treatment of anhedonia
JP2009545573A (ja) サレデュタントとおよびセロトニン再取込みの選択的阻害剤またはセロトニン/ノルエピネフリン再取込みの阻害剤とを組み合わせて含有する医薬組成物
Ilario et al. Neuroleptic malignant syndrome without hyperthermia induced by aripiprazole extended-release injection
Hollander C. 16.01 Anxiety spectrum disorders over life cycle